WallStreetZenWallStreetZen

NASDAQ: SPRB
Spruce Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SPRB

Based on 4 analysts offering 12 month price targets for Spruce Biosciences Inc

Min Forecast
$160.00+166.4%
Avg Forecast
$203.25+238.41%
Max Forecast
$283.00+371.2%

Should I buy or sell SPRB stock?

Based on 4 analysts offering ratings for Spruce Biosciences Inc.

Buy
Strong Buy
0 analysts 0%
Buy
4 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SPRB's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates SPRB as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their SPRB stock forecasts and price targets.

SPRB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-10
lockedlocked$00.00+00.00%2026-03-10
lockedlocked$00.00+00.00%2025-12-23
lockedlocked$00.00+00.00%2025-12-03

1 of 1

Forecast return on equity

Is SPRB forecast to generate an efficient return?

Company
-54.7%
Industry
16.44%
Market
150.38%
SPRB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SPRB forecast to generate an efficient return on assets?

Company
-43.86%
Industry
-4.64%
SPRB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SPRB earnings per share forecast

What is SPRB's earnings per share in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$24.46
Avg 2 year Forecast
-$16.95

SPRB revenue forecast

What is SPRB's revenue in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
$41.1M
Avg 2 year Forecast
$8.0M

SPRB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPRB$60.06$203.25+238.41%Buy
MCRB$8.63$22.00+154.92%Strong Buy
PMVP$1.56N/AN/A
ATYR$0.85$1.00+17.65%Hold
PLRX$1.35$2.67+97.56%Buy
View Top Biotech Stocks

Spruce Biosciences Stock Forecast FAQ

Is Spruce Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: SPRB) stock is to Buy SPRB stock.

Out of 4 analysts, 0 (0%) are recommending SPRB as a Strong Buy, 4 (100%) are recommending SPRB as a Buy, 0 (0%) are recommending SPRB as a Hold, 0 (0%) are recommending SPRB as a Sell, and 0 (0%) are recommending SPRB as a Strong Sell.

If you're new to stock investing, here's how to buy Spruce Biosciences stock.

What is SPRB's earnings growth forecast for 2026-2027?

(NASDAQ: SPRB) Spruce Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 27.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,669.49%.

Spruce Biosciences's earnings in 2026 is -$38,966,000.On average, 6 Wall Street analysts forecast SPRB's earnings for 2026 to be -$33,559,623, with the lowest SPRB earnings forecast at -$66,517,468, and the highest SPRB earnings forecast at $28,755,277.

In 2027, SPRB is forecast to generate -$23,256,129 in earnings, with the lowest earnings forecast at -$57,159,037 and the highest earnings forecast at $23,852,830.

What is SPRB's revenue growth forecast for 2026-2027?

(NASDAQ: SPRB) Spruce Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.25%.

Spruce Biosciences's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast SPRB's revenue for 2026 to be $56,434,873, with the lowest SPRB revenue forecast at $0, and the highest SPRB revenue forecast at $216,823,955.

In 2027, SPRB is forecast to generate $10,985,948 in revenue, with the lowest revenue forecast at $7,529,772 and the highest revenue forecast at $14,550,516.

What is SPRB's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: SPRB) forecast ROA is -43.86%, which is lower than the forecast US Biotechnology industry average of -4.64%.

What is SPRB's Price Target?

According to 4 Wall Street analysts that have issued a 1 year SPRB price target, the average SPRB price target is $203.25, with the highest SPRB stock price forecast at $283.00 and the lowest SPRB stock price forecast at $160.00.

On average, Wall Street analysts predict that Spruce Biosciences's share price could reach $203.25 by Mar 10, 2027. The average Spruce Biosciences stock price prediction forecasts a potential upside of 238.41% from the current SPRB share price of $60.06.

What is SPRB's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: SPRB) Spruce Biosciences's current Earnings Per Share (EPS) is -$50.83. On average, analysts forecast that SPRB's EPS will be -$24.46 for 2026, with the lowest EPS forecast at -$48.48, and the highest EPS forecast at $20.96. In 2027, SPRB's EPS is forecast to hit -$16.95 (min: -$41.66, max: $17.38).

What is SPRB's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: SPRB) forecast ROE is -54.7%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.